← Back to headlines
Ultragenyx Receives FDA IND Clearance for UX016 in GNE Myopathy Treatment
Ultragenyx has announced that its investigational new drug (IND) application for UX016, intended for the treatment of GNE myopathy, has received clearance from the FDA.
30 Mar, 14:38 — 30 Mar, 14:38
Sources
Showing 1 of 1 sources
Related Stories
AI Drone Project Launched to Detect Banana Disease in Davao Region
just now
Chinese Engineers Develop Triple System for Venus Atmosphere Analysis
33m ago
Artemis II Mission Preparations Intensify, Revealing Astronauts, Partners, and Spacesuit Details
35m ago
Neanderthal Diet in Lower Saxony Included Elephant, Bear, and Beaver
36m ago